Can't Miss Webinar—Lupus Nephritis: The ACR Guideline in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: axial spondyloarthritis

How Magnetic Resonance Imaging Technology Can Aid Spondyloarthritis Diagnosis

Larry Beresford  |  

SAN FRANCISCO—“We haven’t made a lot of progress in ensuring the early diagnosis of spondyloarthritis,” said Walter Maksymowych, MD, FRCP, professor of medicine in the Division of Rheumatology at the University of Alberta and chief medical officer at CaRE (Canadian Research and Education) Arthritis, both in Edmonton. Speaking at the California Rheumatology Alliance 2016 Medical…

Bone Loss Common in Suspected Spondyloarthritis

David Douglas  |  

NEW YORK (Reuters Health)—More than 40% of patients with early inflammatory back pain suggestive of axial spondyloarthritis (SpA) show bone loss over the course of two years, according to French researchers. SpA is known to be associated with bone loss at the spine and the hip and an increased risk of vertebral fractures. To investigate…

ACR’s New AS & Nonradiographic Axial SpA Treatment Recommendations

American College of Rheumatology  |  

ATLANTA—The American College of Rheumatology (ACR) has released new recommendations for the treatment of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (SpA). The guideline was developed with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network. It summarizes recommendations for both pharmacologic and non-pharmacologic treatments, including rehabilitation, management of patients with…

EULAR 2014: Research on Rheumatoid Arthritis, Spondyloarthritis

  |  

Latest findings on rheumatological drug therapies, including methotrexate for RA, tumor necrosis factor inhibitors for SpA

Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium

  |  

Therapy with tumor necrosis factor inhibitors, nonsteroidal antiinflammatory drugs, ustekinumab in early stages of osteitis may halt molecular switching to bone-forming phenotype characteristic of SpA

Meeting Management Challenges in axSpA

  |  

At this ACR Convergence 2025 session, experts discussed emerging concepts with axial spondyloarthritis, including the most effective MRI specifications for diagnosis, challenges with axial juvenile spondyloarthritis & the many mimics of axSpA.